Epilepsy is the fourth most common neurological disorder in the U.S. It is estimated that about 3 million adults in the country have active epilepsy. Drug therapy is unable to control seizures for 1 in 3 patients. Drug-resistant epilepsy is a devastating, highly undertreated disease with a significant unmet need.
The company we are profiling today is NeuroPace Inc. (NPCE), a medical device company known for its innovative therapy designed for adults suffering from drug-resistant focal epilepsy, marketed under the name RNS System.
Subscribe to continue reading the article.
This article is part of our premium content offering.Subscribe with a RTTNews subscription.
Subscribe NowAlready subscribed? Sign in
For comments and feedback: editorial@rttnews.com